Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cytarabine versus low-dose cytarabine plus interferon alfa-2a in chronic myeloid leukemia
ISRCTN84226319Phase 3Completed
- Sponsor
- HOVON
- Start
- Jan 1998
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine, interferon alfa-2a, idarubicin and hydroxyurea in chronic myelogenous leukemia (CML) (3 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Jan 1998; status: completed.
02
Drugs
cytarabineinterferon alfa-2aidarubicinhydroxyurea
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN84226319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84226319.